Rallybio (RLYB) is trading down at $16.90 (-1.05%), as of the latest quote. It operates in the Health Care sector.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | $636.0K | $858.0K |
| Growth (year over year) | — | — | — | — | — | +34.9% |
| Operating income | −$25.3M | −$45.6M | −$67.9M | −$78.9M | −$60.5M | −$33.1M |
| Operating margin | — | — | — | — | −9511.9% | −3853.6% |
| Net income | −$26.4M | −$47.0M | −$66.7M | −$74.6M | −$57.8M | −$8.98M |
| Net margin | — | — | — | — | −9084.1% | −1046.4% |
| EPS (diluted) | −$97.28 | −$14.72 | −$16.72 | −$14.72 | −$10.61 | −$1.59 |
| Balance sheet | ||||||
| Cash and equivalents | $140.2M | $175.3M | $57.0M | $24.5M | $13.9M | $31.4M |
| Total assets | $141.9M | $182.2M | $180.4M | $115.6M | $68.1M | $62.3M |
| Total liabilities | $5.86M | $6.58M | $11.1M | $9.44M | $6.45M | $4.30M |
| Shareholders' equity | $136.0M | $175.6M | $169.3M | $106.2M | $61.7M | $58.0M |
| Cash flow | ||||||
| Operating cash flow | −$22.0M | −$45.5M | −$57.3M | −$60.3M | −$49.3M | −$29.8M |
| Capital expenditure | $137.0K | $333.0K | $54.0K | $12.0K | $0 | — |
| Free cash flow | −$22.2M | −$45.9M | −$57.3M | −$60.3M | −$49.3M | — |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $299.0K | — | $212.0K | $212.0K | $212.0K | $222.0K | $212.0K | $0 |
| Growth (year over year) | — | — | — | −29.1% | −29.1% | — | 0.0% | −100.0% |
| Operating income | −$12.1M | — | −$9.67M | −$10.1M | −$6.92M | −$6.41M | −$8.73M | −$5.65M |
| Operating margin | −4035.5% | — | −4561.3% | −4743.9% | −3266.5% | −2888.3% | −4119.3% | — |
| Net income | −$11.5M | — | −$9.44M | −$9.70M | $16.0M | −$5.85M | −$8.28M | $43.7M |
| Net margin | −3834.8% | — | −4452.4% | −4576.9% | 7554.7% | −2636.0% | −3904.7% | — |
| EPS (diluted) | −$2.08 | — | −$1.69 | −$1.76 | $2.88 | −$1.02 | −$1.46 | $7.53 |
| Balance sheet | ||||||||
| Cash and equivalents | $25.3M | $13.9M | $14.8M | $9.45M | $32.1M | $31.4M | $41.3M | $92.8M |
| Total assets | $79.0M | $68.1M | $58.0M | $51.0M | $67.7M | $62.3M | $54.5M | $98.1M |
| Total liabilities | $8.19M | $6.45M | $3.91M | $5.04M | $4.63M | $4.30M | $4.20M | $3.57M |
| Shareholders' equity | $70.8M | $61.7M | $54.1M | $46.0M | $63.0M | $58.0M | $50.3M | $94.5M |
| Cash flow | ||||||||
| Operating cash flow | −$13.5M | — | −$10.2M | −$8.38M | −$6.55M | −$4.68M | −$7.98M | $45.9M |
From Rallybio's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Rallybio in our feed yet.